Special Issue

Therapeutic Resolution of Pulmonary Arterial Hypertension

Message from the Guest Editor

Pulmonary Arterial Hypertension (PAH) is a devastating cardiovascular disorder caused by the narrowing of blood vessels in the lungs and, in the absence of therapy, leads to right heart failure and premature death. The genetic architecture of PAH has been explored over the last twenty years, identifying a number of genes and highlighting the involvement of numerous pathways and risk factors for exploration. There is no cure for this disorder. Current management therapies for PAH are very costly and aim to improve symptoms. Hence, there is a need to identify novel therapeutic interventions. This Special Issue of BioChem will pay attention to the recent advances in PAH research. Topics include, but are not limited to:

- Molecular genetic basis of PAH
- The role of epigenetics in the pathogenesis of PAH
- Repurposing established drugs for the resolution of PAH
- Therapeutic resolution of PAH using natural products
- Current treatments of PAH and their limitations
- The prospects of biologics for the treatment of PAH
- Resolution of PAH using small molecule agents and gene therapy

Guest Editor

Dr. Talat Nasim

School of Pharmacy and Medical Sciences, University of Bradford, Bradford BD7 1DP, UK

Deadline for manuscript submissions

closed (31 August 2024)

BioChem

an Open Access Journal by MDPI

Indexed in Scopus

mdpi.com/si/110376

BioChem
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biochem@mdpi.com

mdpi.com/journal/biochem

BioChem

an Open Access Journal by MDPI

Indexed in Scopus

mdpi.com/journal/biochem

MDPI

About the Journal

Message from the Editor-in-Chief

BioChem is an international and interdisciplinary open access journal encompassing the fields of molecular biology, cell biology, structural biology, nucleic acid biology, chemical biology, synthetic biology, disease biology, biophysics, and theoretical biochemistry. It publishes reviews, research articles, communications, and letters. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible.

Editor-in-Chief

Prof. Dr. Buyong Ma
School of Pharmacy, Shanghai Jiaotong University, Shanghai, China

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, EBSCO and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 33.9 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).